NCT03010579

Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation

Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Peking University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is an randomized trial to evaluate the potential benefit of erythropoietin in the treatment of anemia in patients with lymphoma after autologous hematopoietic stem cell transplantation.

Detailed description

Lymphoma patients with anemia on day +15 post-transplant will be randomized to erythropoietin group or control group. Potential benefit of erythropoietin will be evaluatedon day +60 post-transplant.

Conditions

• Anemia
• Lymphoma
• Hematopoietic Stem Cell Transplantation

Interventions

Type	Name	Description
DRUG	erythropoietin	Erythropoietin will be administered subcutaneously (s.c.) at the dose of 10 000 IU, three times a week. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
DRUG	iron supplementation	If necessary, oral ferrous succinate, vitamins B12 and folic acid will be administered.

Timeline

• Start date: 2016-10-01
• Primary completion: 2017-12-01
• Completion: 2018-12-01
• First posted: 2017-01-05
• Last updated: 2017-01-05

Locations

1 site across 1 country: China